The ACROSS HF programme has been established as a collaboration between leading international experts to share their knowledge and best clinical practice with colleagues who manage patients with heart failure (HF). This programme represents a vision of a multidisciplinary and collaborative approach to the management of HF.
There is an overwhelming need for treatments that improve outcomes for patients with HF. Over 60 million patients have been diagnosed with HF globally and, despite recent advances, ~75% of patients diagnosed with HF with reduced ejection fraction die within 5 years, and there are currently no effective treatment options available for patients with HF with preserved ejection fraction. The healthcare community is faced with the urgent need to prioritise discussions around HF management by disseminating balanced and scientifically robust evidence.
Recent cardiovascular outcomes trials determining the cardiovascular benefit–risk profile of glucose-lowering therapies have uncovered potential treatment options for patients with HF. The ACROSS HF educational modules provide details of recent and current trials in HF, including study design, efficacy and safety results, to enable physicians worldwide to better evaluate the clinical relevance of this evidence.
The ACROSS HF materials are developed in collaboration with an esteemed Steering Committee to provide a holistic overview of the pathophysiology, comorbidities and emerging treatment options in patients with HF.